Conolidine’s analgesic results stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors during the central anxious process, conolidine modulates alternate molecular targets. A Science Improvements study observed that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://angelopehpj.blog-mall.com/39529458/the-2-minute-rule-for-conolidin-to-replace-traditional-painkillers